Walgreens Boots Alliance, Inc. (WBA)

Over the past six months, Walgreens Boots Alliance's stock price has experienced fluctuations. The 52-week high for WBA stock was $13.25, and the 52-week low was $8.08. As of late June 2025, the share price was around $11.45, representing a slight decline of 1.12% over the period from July 1, 2024, to June 27, 2025. Key events impacting the stock include fiscal 2025 first and third quarter results, the acquisition announcement by Sycamore Partners, credit rating downgrades, and cost-cutting measures and retail declines.

Demand for Walgreens Boots Alliance's products and services exhibits seasonality, particularly for certain categories. The company uses AI to forecast demand and optimize its supply chain, considering seasonal trends and flu outbreaks. Walgreens also runs seasonal promotions to align with consumer behavior, such as summer savings on seasonal essentials. Predicting and responding to consumer purchasing habits is crucial to avoid sales declines or excess inventory.

Walgreens Boots Alliance, Inc. is an integrated healthcare, pharmacy, and retail leader with a 175-year heritage. The company operates as a global innovator in retail pharmacy, serving millions of customers and patients daily. WBA is classified within the Healthcare sector and the Pharmaceutical Retailers industry. WBA's core operations are divided into three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The company dispenses medicines, improves access to pharmacy and health services, and provides health and beauty products. Major products and services include prescription drugs, over-the-counter medications, health and wellness products, beauty items, and general merchandise. Key consumer brands include Walgreens, Boots, Duane Reade, No7 Beauty Company, and Benavides. Walgreens also has its own branded line of products called "Well at Walgreens." The company has been expanding its healthcare services to include in-store clinics and telehealth.

Walgreens Boots Alliance has a global presence, operating in eight countries with approximately 12,500 retail stores and healthcare locations. While operating in around 25 countries, most revenue is from the U.S. Its pharmacy-led retail business is in 11 countries, and its pharmaceutical wholesale and distribution network extends to 19 countries. In the U.S., Walgreens and Duane Reade stores are in all 50 states, D.C., Puerto Rico, and the U.S. Virgin Islands, with approximately 78% of the U.S. population living within five miles of a Walgreens or Duane Reade pharmacy.

Walgreens Boots Alliance aims to improve lives through better health and is recognized as a trusted innovator in retail pharmacy. The company emphasizes contributions to healthy communities, the planet, an inclusive workplace, and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index. Events affecting WBA's reputation include opioid-related legal settlements, strategic partnerships and initiatives, and a focus on digital transformation and healthcare services.

Walgreens Boots Alliance, Inc. is primarily owned by institutional shareholders, who held approximately 59.57% of the company's shares as of 2024, and about 61.65% as of March 2025. Insiders hold a smaller percentage, approximately 0.74% as of March 2025. Major institutional owners as of March 31, 2025, include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. The largest individual shareholder is Stefano Pessina, who owns 783.09 million shares, representing 90.47% of the company.